SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
OXIGENE INC. (OXGN)
An SI Board Since January 1997
Posts SubjectMarks Bans Symbol
273 25 0 OXGN
Emcee:  sloan Type:  Unmoderated
Introduction Market Data Compact
DOES ANYONE OUT THERE FOLLOW THIS COMPANY? wHERE CAN I GET
SOME INFORMATION ?
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
273OXiGENE and VDA's in general. Are they working? This article earningsview.Doctor Zeus-12/14/2010
272Hi all, Yesterday I short OXGN for the first time. But, I'm not yet able towww_9hub_Net-5/23/2009
271Here's some additional work that supports this trial (thanks to Rick for thetuck-10/24/2006
270U.S. FDA Grants Orphan Drug Designation to OXiGENE`s Lead Clinical Candidate, CoLJM-5/15/2006
269OXiGENE Completes Patient Enrollment in a Phase II Clinical Trial Evaluating CA4Rutgers-3/23/2006
268OXiGENE to Commence First Ever Oncology Clinical Trial Combining a Vascular DisrJohn McCarthy-12/5/2005
267Good at starting trials, bad at finishing: investorshub.comDewDiligence_on_SI-10/28/2005
266Antisoma AS1404 results: tinyurl.comDewDiligence_on_SI-10/17/2005
265thass nice. (John Metcalf.... I remember the punch line, but not the joke) scaram(o)uche-2/18/2005
264OXGN is a quasi-scam, IMHO. <i>Talk biotech at www.tinyurl.com/zaqn</iDewDiligence_on_SI-2/18/2005
263In mice - BFD. Lost interest in OXGN a long time ago.nigel bates-2/16/2005
262"OXiGENE's lead compound Combretastatin A4 Prodrug (CA4P) enhances the Nikole Wollerstein-2/16/2005
261Combretastatin A4 phosphate: background and current clinical status. Young SL,Nikole Wollerstein-8/29/2004
260Interesting rally for the last 3 days Combretastatin A4 phosphate (CA4P) is a wNikole Wollerstein-5/15/2004
259100 might be conservative"" I do not know the rosy scenario will be tNikole Wollerstein-10/2/2003
258"What an idiotic recomendationes: if CAP4 work OXGN goes too 100 if not tooschzammm-9/30/2003
257OXiGENE's CA4P Becomes First Vascular Targeting Agent to be Combined with Moschzammm-9/30/2003
256"OXiGENE started with a Mkt Outperform rating at Rodman & Renshaw; targNikole Wollerstein-9/12/2003
255Good move. Unfortunately and fortunately I sold 80% yesterday afternoon and the schzammm-7/29/2003
254I sold. First thing in the morningNikole Wollerstein-7/28/2003
253Oxigene's shares jump 70% on drug's 'orphan' status marketwatchschzammm-7/28/2003
252Progress report on Phase I trials of Combretastatin A4 Phosphate (CA4P) and DimeNikole Wollerstein-7/26/2003
251PEREGRINE AND OXiGENE CONCLUDE ARCUS THERAPEUTICS LLC JOINT VENTURE Companies nigel bates-3/1/2002
250WATERTOWN, Mass.--(BW HealthWire)--Nov. 26, 2001--OXiGENE, Inc. (NASDAQ, SSE: OXnigel bates-11/26/2001
249>>WATERTOWN, Mass.--(BW HealthWire)--Oct. 31, 2001-- OXiGENE, Inc. (Nasdaqtuck-10/31/2001
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News